ARTICLE | Financial News
Sarepta planning $100 million follow-on
April 23, 2014 12:03 AM UTC
Sarepta Therapeutics Inc. (NASDAQ:SRPT) proposed late Tuesday to raise up to $100 million in a follow-on underwritten by BofA Merrill Lynch and Morgan Stanley. On Monday, Sarepta jumped $9.58 (39%) to $33.98 after the company said it plans to submit an NDA to FDA for eteplirsen ( AVI-4658) to treat Duchenne muscular dystrophy (DMD) by year end. In November, the company fell after saying approval of eteplirsen could be delayed by at least two years (see BioCentury Extra, April 21). ...